ArticleCureus2026
Early Treatment-Related Mortality in Acute Leukemia: A Real-World, Single-Center Study From a Resource-Limited Setting.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives Treatment-related mortality (TRM) remains a significant barrier to successful outcomes in acute leukemia despite therapeutic advances. This study aimed to evaluate the frequency, clinical features, and risk factors associated with early TRM in a real-world cohort from a resource-limited setting, defined as death occurring within 30 days of treatment initiation. The primary aims of this study were to evaluate the incidence and timing of early death (ED) and TRM across different blood cancer classifications. The secondary aim was to identify the specific clinical causes, such as infectious complications, hemorrhagic events, or refractory disease, that drive these fatalities. Methods We retrospectively analyzed 155 patients aged 14 to 100 years diagnosed with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), acute promyelocytic leukemia (APL), or acute undifferentiated leukemia (AUL) between 2016 and 2025 at a single tertiary center in Iraq. Patients received standard treatment protocols, including the 3+7 regimen, UKALL XC, ATRA/ATO (all-trans retinoic acid and arsenic trioxide), hyper-CVAD (hyper-fractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone), azacitidine, ATRA/idarubicin, and others. Results The overall TRM rate was 9.0% (14/155). APL patients demonstrated the highest mortality at 28.6% (8/28), followed by ALL at 5.1% (3/59), and AML at 4.5% (3/66). Female patients accounted for 78.6% of deaths. The principal causes were sepsis (42.9%), differentiation syndrome (28.6%), intracranial hemorrhage (21.4%), and alveolar hemorrhage (7.1%). No statistically significant differences in clinical parameters were observed between patients with ED and those without ED. Conclusions TRM rates remain substantial, particularly among APL patients, with infection representing the predominant cause. These real-world findings highlight the need for early risk recognition, rapid supportive care, and improved treatment pathways for acute leukemia in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.